BR0102300A - Formas cristalinas de ácido (3s-trans)-2-[3,4-di-hidro-4-hidróxi-3-(fenilmetil)-2h-1 -benzopiran-7-il]-4-(trifluorometil)-benzóico - Google Patents

Formas cristalinas de ácido (3s-trans)-2-[3,4-di-hidro-4-hidróxi-3-(fenilmetil)-2h-1 -benzopiran-7-il]-4-(trifluorometil)-benzóico

Info

Publication number
BR0102300A
BR0102300A BR0102300-4A BR0102300A BR0102300A BR 0102300 A BR0102300 A BR 0102300A BR 0102300 A BR0102300 A BR 0102300A BR 0102300 A BR0102300 A BR 0102300A
Authority
BR
Brazil
Prior art keywords
new
compound
benzoic
trans
hydroxy
Prior art date
Application number
BR0102300-4A
Other languages
English (en)
Inventor
Douglas John Meldrum Allen
David Bruning Joseph
Nancy Anne Sage
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0102300A publication Critical patent/BR0102300A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: "FORMAS CRISTALINAS DE áCIDO (3S-TRANS)-2-[3,4-DI-HIDRO-4-HIDRóXI-3-(FENILMETIL)-2H-1 -BENZOPIRAN-7-IL]-4-(TRIFLUOROMETIL)-BENZóICO". A presente invenção refere-se a novas formas polimórficas de ácido (3S-trans)-2-[3,4-di-hidro-4-hidroxi-3-(fenilmetil)-2H-1 -benzopiran-7ill-4-(trifluorometil)-benzóico anidro cristalino, doravante designado por composto (1), e um novo sal, e um hidrato do referido composto, onde cada nova composição tem características particulares que contribuem para o seu uso em formulações farmacêuticas. Está descrito o novo monohidrato de composto (1), que pode ser vantajosamente isolado a partir de solventes umedecidos com água e formulados por meio de técnicas de granulação a úmido. Está também descrito o novo (mono) sal de etilenodiamina e demonstra solubilidado e biodisponibilidade de nível superior. Adicionalmente, estão descritas as formas polimórficas A e B de composto (1) anidro cristalino, onde a forma A tem uma estabilidade térmica superior, e a forma B tem uma solubilidade superior. Adicionalmente, estão descritas composições farmacêuticas que compreendem estas substâncias e métodos para o tratamento de respectivos estados de doença, em particular o tratamento de doenças inflamatórias.
BR0102300-4A 2000-06-08 2001-06-07 Formas cristalinas de ácido (3s-trans)-2-[3,4-di-hidro-4-hidróxi-3-(fenilmetil)-2h-1 -benzopiran-7-il]-4-(trifluorometil)-benzóico BR0102300A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21053800P 2000-06-08 2000-06-08

Publications (1)

Publication Number Publication Date
BR0102300A true BR0102300A (pt) 2002-02-13

Family

ID=22783290

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0102300-4A BR0102300A (pt) 2000-06-08 2001-06-07 Formas cristalinas de ácido (3s-trans)-2-[3,4-di-hidro-4-hidróxi-3-(fenilmetil)-2h-1 -benzopiran-7-il]-4-(trifluorometil)-benzóico

Country Status (6)

Country Link
US (1) US6436987B1 (pt)
EP (1) EP1167363A3 (pt)
JP (1) JP2002030080A (pt)
BR (1) BR0102300A (pt)
CA (1) CA2349776A1 (pt)
MX (1) MXPA01005769A (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745800A4 (en) * 2004-04-26 2009-11-18 Ono Pharmaceutical Co NEW BLT2-MEDIATED DISEASE AND BLT2 BINDING AND CONNECTION
CA2574627A1 (en) * 2004-07-22 2006-02-02 Pharmacia Corporation Compositions for treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist
SI3133070T1 (sl) 2009-11-27 2019-11-29 Genzyme Corp Eliglustat (GENZ 112638) kot inhibitor sintaze glukozilceramida za uporabo v postopku zdravljenja Fabrjyeve ali Gaucherjeve bolezni, kjer postopek obsega prilagajanje individualnega terapevtskega odmerka metabolizmu P-450 pacienta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2745305A1 (de) 1977-10-07 1979-04-19 Bayer Ag Insektizide und akarizide mittel
US4565882A (en) 1984-01-06 1986-01-21 G. D. Searle & Co. Substituted dihydrobenzopyran-2-carboxylates
CA1320490C (en) 1987-01-12 1993-07-20 Darrel M. Gapinski Anti-inflammatory agents
US4889871A (en) 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
MX9300312A (es) * 1992-01-23 1993-07-31 Pfizer Antagonistas benzopiranicos y relacionado de ltb.
UA58520C2 (uk) * 1996-09-16 2003-08-15 Пфайзер, Інк. Спосіб та проміжні сполуки для одержання похідних заміщеного хроманолу

Also Published As

Publication number Publication date
JP2002030080A (ja) 2002-01-29
EP1167363A2 (en) 2002-01-02
US20020035144A1 (en) 2002-03-21
CA2349776A1 (en) 2001-12-08
MXPA01005769A (es) 2003-08-20
EP1167363A3 (en) 2002-02-06
US6436987B1 (en) 2002-08-20

Similar Documents

Publication Publication Date Title
HRP20050663A2 (en) Malonamide derivatives as gamma-secretase inhibitors
BR0213612A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
ME00466B (me) Tartaratne soli 5,8,14-triazatetraciklo( 10.3.1.02,11.04,9)-heksadeka-2 (11),3,5,7,9-pentaena
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
PE20001032A1 (es) Composiciones y metodos para tratar enfermedades pulmonares
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
EA200601802A1 (ru) Производные морфолина
BR0213760A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
TNSN04165A1 (en) Substituted hydroxyethylamines
DE60126947D1 (de) Behandlung der glykogenspeicherkrankheit typ ii
BR0307782A (pt) Compostos azabiciclo para o tratamento de doença
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
DE60230066D1 (de) Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten
PE20040767A1 (es) Derivado hemisulfato de azido citosina cristalino anhidro
NO20054662L (no) Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
HUP0400545A2 (hu) Uro-szelektív alfa1-adrenoceptor gátlóanyagokként használatos 1,4-diszubsztituált piperazinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BR0102300A (pt) Formas cristalinas de ácido (3s-trans)-2-[3,4-di-hidro-4-hidróxi-3-(fenilmetil)-2h-1 -benzopiran-7-il]-4-(trifluorometil)-benzóico
BR0306701A (pt) Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal
BRPI0416535A (pt) processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
MXPA05012369A (es) Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.